In short
Clinical trials investigating Glyceryl Trinitrate are studying how it is used in different patient groups, mainly to assess treatment effects and outcomes. The trials in this article include people with heart-related conditions, MINOCA, and esophageal food impaction, and they measure results such as symptom relief, quality of life, and need for procedures.
Key points
- Clinical trials investigating Glyceryl Trinitrate are being done in several different patient groups, not just one disease area. The source data includes studies in MINOCA, stable angina, esophageal food impaction, subclinical heart failure, type 2 diabetes, and kidney transplant patients. Most of the trials are Phase 3, with one Phase 2 study. The main outcomes include symptom relief, quality of life, exercise time, heart structure and function, and whether patients avoid procedures such as endoscopic removal. Trial status varies from authorised to suspended and completed.
Trial overview
The source data includes one trial that directly studies Glyceryl Trinitrate in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA). Other trials in the data set include products such as nitroglycerin or Nitrolingual/Nitrospray, but those are separate studies and are not the same as Glyceryl Trinitrate.
Conditions studied
The Glyceryl Trinitrate trial in the source data is in patients with MINOCA, which means a heart attack with no major blockage in the coronary arteries. The trial is designed to test a precision-medicine approach, meaning treatment based on the likely cause of the condition rather than the same treatment for everyone.
Although the full trial set covers several other conditions, those studies do not list Glyceryl Trinitrate as the study drug.
Who can participate
The Glyceryl Trinitrate study includes patients with MINOCA. The data does not give a full list of eligibility rules, but the target group is clearly adults with this specific heart condition.
Other trials in the source data include women with asymptomatic heart failure, patients with stable angina, kidney transplant patients, people with type 2 diabetes, and patients with esophageal food impaction. These are different study groups and should not be confused with the Glyceryl Trinitrate trial itself.
Trial phases and status
The Glyceryl Trinitrate study is a Phase 3 trial and is listed as completed. Phase 3 means the study is in a later stage and is usually designed to see how well a treatment works in a larger group of people.
In the wider set of trials, most studies are also Phase 3, while the esophageal food impaction study is Phase 2. Status also varies, with studies listed as authorised, suspended, or completed.
Main endpoints and outcomes
The main endpoint for the Glyceryl Trinitrate trial is angina status and quality of life measured with the Seattle Angina Questionnaire at 1-year follow-up. This means the researchers want to know how patients feel, how often they have chest pain symptoms, and how the condition affects daily life.
Other trials in the source data measure different outcomes, such as exercise duration, adverse events, laboratory abnormalities, heart structure, heart pumping function, vascular function, and whether a food impaction is resolved without endoscopic removal. These are important because they show how clinical trials can focus on both benefits and safety.
Study details by trial
The completed Glyceryl Trinitrate study is the PROMISE study, which tested a precision-medicine approach in MINOCA and followed patients for 1 year using the Seattle Angina Questionnaire. Its enrollment was 145 participants, and it was a Phase 3 interventional study.
Other interventional studies in the data include the TREASURE trial in subclinical heart failure, the ORESA study in stable angina, BELAFENDO in kidney transplant patients, the STENO INTEN-CT study in type 2 diabetes, and a study of nitroglycerin for esophageal food impaction.
- TREASURE trial: Phase 3, authorised, 130 people, studying subclinical heart failure and cardiac remodeling outcomes.
- ORESA study: Phase 3, suspended, 769 people, studying stable angina and exercise duration.
- BELAFENDO: Phase 3, authorised, 44 people, studying kidney transplant patients and blood vessel function.
- STENO INTEN-CT: Phase 3, authorised, 7300 people, studying type 2 diabetes and a composite cardiovascular endpoint.
- Nitroglycerin for Esophageal Food Impaction: Phase 2, authorised, 88 people, studying whether food impaction can be resolved without endoscopic removal.